RESUMO
Background: Diabetes as the leading cause of mortality and morbidity, have been increased by about 35% from 2011 to 2015 worldwide. The objective of this study was to assess the trend and pattern of diabetes and prediabetes prevalence in Iran and also evaluate the diagnosis and status of diabetes management. Methods: The results of this study are extracted from the National Stepwise approach to non-communicable disease risk factor surveillance (STEPS), conducted in 2007, 2011, 2016, and 2021 in Iran. We evaluated all obtained data by questionnaires (demographic, epidemiologic, risk-related behavioral data), physical measurements, and laboratory measures. Results: The prevalence of diabetes almost doubled from 2007 to 2021 among adults 25 years old and above. Diabetes prevalence increased from 10.85% (95% CI:10.30-11.40) in 2016 to 14.15% (13.42-14.87) in 2021. Prediabetes prevalence increased from 18.11% (17.46- 18,76) in 2016 to 24.81% (23.88-25.74) in 2021. Diabetes diagnosis stayed constant hence; diabetes coverage improved from 56.87% (54.21-59.52) to 65.04% (62.40- 67.69). Despite an enhancement in diabetes diagnosis and coverage, diabetes effective care did not improve significantly during 2016 and 2021, with a number of 35.98% (32.60- 39.36) in 2016 and 31.35% (28.20- 34.51) in 2021. Conclusion: The prevalence of diabetes and prediabetes in Iran is almost doubled during the past 14 years. Although, several health policies had been developed to improve the screening and quality of diabetes care; there are still significant gaps in the effective control of diabetes. Accordingly, the current care plan should be reviewed. Supplementary Information: The online version contains supplementary material available at 10.1007/s40200-023-01308-z.
RESUMO
BACKGROUND: Lung cancer is a major cause of cancer-related deaths worldwide. There are conflicting results regarding the role of sirtuin-1 in cancer. This study aimed to evaluate the serum sirtuin-1 levels in patients with lung cancer and its relationship with the quality of life based on Karnofsky performance statue scale (KPS). METHODS: Serum sirtuin-1 levels were measured in 30 male patients with lung cancer and 50 healthy men. The two groups were matched for age. The difference between the serum levels of sirtuin-1 between the two groups and its relationship with KPS and other clinical parameters were evaluated. Data were analyzed by independent t-test and Pearson correlation, and P < 0.05 was considered as significant. RESULTS: Sirtuin-1 levels were significantly lower in the patients in comparison with healthy subjects (P < 0.001). There was also a significant relationship between the serum level of sirtuin-1 with KPS (P < 0.001, r = 0.634), arterial oxygen saturation (P < 0.01, r = 0.470), and smoking history (P < 0.01, r = -0.330). In addition, the serum sirtuin-1 levels were significantly lower in adenocarcinoma than that in squamous cell carcinoma or small cell lung cancer (p < 0.001 and P < 0.05, respectively). CONCLUSION: The serum levels of sirtuin-1 were lower in patients with lung cancer. In addition, there was a significant correlation between serum levels of sirtuin-1 and KPS, O2 saturation, and smoking history. Further serological and histological studies seem to be necessary due to the existence of conflicting reports regarding sirtuin-1.
